SCH772984

SCH772984 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 13;14(1):802. [Abstract]

Customer Validation
SCH772984 upregulates Mbp and Ng2, as well as significantly reduces Cd74 and Erk1/2, in primary neuronal cultures from control and Alzheimer’s disease knock-in mice (Fig. i and j).

SCH772984 purchased from MedChemExpress. Usage Cited in: Acta Biomater. 2019 Feb:85:106-116. [Abstract]

Customer Validation
Western analysis of related protein expression in the treatment of DBM/CBD-IKVAV-cRGD, DBM/CBD-IKVAV-cRGD + FAK inhibitor PF-573228 or DBM/CBD-IKVAV-cRGD + ERK inhibitor SCH772984.

SCH772984 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2019 Jan 29;9(1):907. [Abstract]

Customer Validation
HCT116 cells are treated with different concentrations of PD0325901 or SCH772984 before cells are harvested for western blotting analysis for ERK1/2 and phosphorylated ERK1/2

SCH772984 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2019 Jan 29;9(1):907. [Abstract]

Customer Validation
HCT116 cells are first treated with different concentrations of PD0325901 or SCH772984 for 36 h and are then treated without or with MG132 for 12 hours before harvested for analysis of the levels of proteins by western blotting using antibodies as indicated.

SCH772984 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2019 Jan 29;9(1):907. [Abstract]

Customer Validation
KYSE70 cells are first treated with different concentrations of PD0325901 or SCH772984 for 36 hours and are then treated without or with MG132 for 12 hours before cells are harvested for western blotting using antibodies as indicated.

SCH772984 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Feb 15;78(4):891-908. [Abstract]

Customer Validation
A549 cells are treated with 10 μM SCH772984 (ERK1/2 inhibitor) or DMSO for 16 hr and analyzed for PSC formation by immunostaining

SCH772984 purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

Customer Validation
BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM)+SCH772984 (10 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 6 h.

SCH772984 purchased from MedChemExpress. Usage Cited in: J Immunol Res. 2018 Jun 7:2018:6249085. [Abstract]

Customer Validation
The level of p-ERK1/2 expression is suppressed by SCH772984. RAW264.7 cells are preincubated with 1 μM SCH772984 for 2h followed by treatment with 20 μg/mL ox-LDL for 24 h.

SCH772984 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Jan 1;495(1):781-786. [Abstract]

Customer Validation
Representative images of migrated cells. HUVECs are pretreated with PD98059 (10 μM), SCH772984 (500 nM) or mock control for 2 h, and seeded in upper chambers of transwell inserts. VEGF (100 ng/ml), Scg3 (1 μg/ml) or PBS in medium with reduced FBS is added to bottom chambers in the presence or absence of the inhibitor. After culturing for 4 or 20 h, cells migrated to the lower surface of transwell membrane are stained with DAPI.

SCH772984 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2017 Nov 25;14(1):228. [Abstract]

Customer Validation
HSP70 release is reversed by ERK1/2 inhibitor in SH-SY5Y cells. SCH772984 (ERK1/2 inhibitor, 2 μM) is given 15 min. Supernatants are collected and analyzed by western blot (n=3).

SCH772984 purchased from MedChemExpress. Usage Cited in: Neurotox Res. 2017 Nov;32(4):535-543. [Abstract]

Customer Validation
Lithium promotes autophagy flux by activating MEK/ERK pathway in cells. Original Western blot showing LC3-II and p62 abundance following treatment with lithium in the presence of PD184352 and SCH772984 in neurons. Arithmetic means±SEM (n=5) showing LC3-II abundance following treatment with lithium in the presence of PD184352 and SCH772984 in neurons.

SCH772984 purchased from MedChemExpress. Usage Cited in: University of Melbourne. 2017 Sep.

Customer Validation
Western blot analysis is performed on protein lysates from exponentially growing melanoma cell lines following 24 hours treatment with 0.1% DMSO as a vehicle control or: GSK1120212 (GSK212) 100 nM; GDC0623 100 nM or SCH772984 1 µM.

SCH772984 purchased from MedChemExpress. Usage Cited in: Okayama University. 2015.

Customer Validation
Expression of Sema4D and PlexinB1 in various oral squamous cell carcinoma cell lines following the addition of IGF-I. Notably, the addition of IGF-I resulted in increased expression of Sema4D, particularly in HSC-2 and SAS cells. This increase was suppressed when IGF-I was administered in the presence of inhibitors targeting its receptor or downstream signaling pathways. No changes in PlexinB1 expression were observed following the addition of IGF-I.